Summary
This 8-K filing from Pfizer Inc. (PFE) on April 29, 2013, details the results of their Annual Meeting of Shareholders held on April 25, 2013. The primary purpose of the filing is to report the voting outcomes on various proposals, including the election of directors, ratification of the independent auditor, and shareholder proposals. All director nominees were overwhelmingly elected, and the appointment of KPMG LLP as the independent registered public accounting firm for 2013 was ratified with significant shareholder support. The filing also shows that shareholders approved, on an advisory basis, the compensation of Named Executive Officers. However, two shareholder proposals, one regarding executive equity retention and another concerning action by written consent, did not receive majority approval from the shareholders. This suggests that while management's compensation practices and auditor choice were supported, shareholders are cautious about certain governance-related proposals.
Key Highlights
- 1All nominated directors were overwhelmingly elected to serve one-year terms.
- 2Shareholders ratified the appointment of KPMG LLP as Pfizer's independent registered public accounting firm for the fiscal year 2013.
- 3The advisory vote on the compensation of the company's Named Executive Officers ('Say-on-Pay') received majority approval.
- 4A shareholder proposal requesting executive equity retention did not pass, indicating shareholder disagreement on this specific governance matter.
- 5Another shareholder proposal concerning the ability of shareholders to take action by written consent was also not approved.
- 6The Annual Meeting of Shareholders took place on April 25, 2013.